Independent

[flipper44]

One last thing on the Survaxm 2b trial, everything looks even worse when you take into account randomization does not take place until about four months after enrollment. That means all those enrollment numbers and dates I provided tighten up even further, because the survival measurements have and will initiate at date of randomization.

For example,

I’ve taken my previous paragraphs below and converted from enrollment to likely/approximate randomization dates.

The way it was randomized.

1. First patient March 2022.
2. 69th patient August 2023.
3. 205th patient May 2024.
3. 228th patient (June 2024?) (randomization complete?) (137 Survax patients and 91 placebo patients)

Interim Analysis.

1. Approximately January 2025, but published decision to continue the trial on February 2025. Apparently, 50% of death events occurred to trigger first interim analysis.

Alright, instead of getting tied up editing and re-editing today, here is the skinny, imo.
For the sake of simplicity, ball park (shift) all randomizations to approximately one month — November 2023. 50% reached 14 months later. Also note, 3 Survax to 2 placebo ratio. Just my opinion. 😢 Survaxm is in trouble, imo.